Clinical Trial Search

Primary: Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment — 15.03; 14.93 events per…

Primary: Overall Response Rate (ORR) — 59.7 percentage of participants — p=<=0.0001

Primary: Proportion of Subjects Achieving a Reduction of at Least 25% of the Volume of the Rectum Receiving at Least 70 Gy. — 24 Participants

Primary: Change From Baseline St. Mark's (Vaizey) Score — -5.5; -4.4; -4.5; -3.4 units on a scale — p=0.092

Primary: Maximum Tolerated Dose — 1.8; 1.5 mg/m^2 of Bortezomib

Primary: Medication Adherence as Assessed by the Medication Event Monitoring System (MEMS) Cap — 52.2; 27.2 percentage of participants

Primary: Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) — 10.93; 10.25; 10.84 percentage of participants

Primary: Mean Number of Adherent Sets of Symbicort Puffs Per Day Over the 26-Week Study Period — 1.3; 1.6 Adherent sets of puffs / day — p=<0.001

Primary: Campylobacteriosis — 13; 11 Participants

Primary: Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Programmed…

Primary: the Percentage of Smears, That Were Difficulty in Making a Definite Diagnosis — 0; 0 percentage of smears

Primary: Number of Subjects With Any Grade 2 and Grade 3 General Adverse Events (AEs) - Solicited and Unsolicited — 32; 30; 24; 27 Participants

Primary: Change in Time to Exhaustion — 568; 552 seconds

Primary: Cmax for Lomitapide — 0.570; 0.436; 1.70; 1.01 ng/mL

Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants